Overview

Lopinavir (LPV) Dose Reduction

Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to study the pharmacokinetics profiles of generic lopinavir/ritonavir and Pediatric Aluvia® at reduced dose by assessing safety, tolerability and efficacy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
The HIV Netherlands Australia Thailand Research Collaboration
Collaborator:
Ministry of Education, Thailand
Treatments:
Lopinavir
Ritonavir